iloprost has been researched along with Asthma* in 4 studies
1 trial(s) available for iloprost and Asthma
Article | Year |
---|---|
Iloprost inhalation in mild asthma.
To determine the feasibility of administering iloprost by inhalation in patients with mild atopic asthma.. Volunteers underwent supervised inhalation of iloprost in the clinic with measurement of spirometry and blood pressure for 2 hours. The volunteers then inhaled iloprost four times daily at a dose of 2.5 or 5 μg for 14 days. Spirometry, asthma questionnaires, peak flow diaries, measurement of methacholine responsiveness, and exhaled nitric oxide concentrations were obtained prior to and after the treatment period.. Chronic inhalation of iloprost (2.5-5 μg) did not alter spirometry or methacholine responsiveness.. Inhaled iloprost in carefully selected volunteers with mild asthma appears to be a suitable intervention to explore the effects of prostacyclin in human asthma. Topics: Administration, Inhalation; Adult; Asthma; Blood Pressure; Bronchial Hyperreactivity; Dose-Response Relationship, Drug; Female; Humans; Iloprost; Male; Middle Aged; Nitric Oxide; Prostaglandins I; Spirometry | 2012 |
3 other study(ies) available for iloprost and Asthma
Article | Year |
---|---|
Identification of potential biomarkers and pathogenesis in neutrophil-predominant severe asthma: A comprehensive bioinformatics analysis.
Airway neutrophilia has been associated with asthma severity and asthma exacerbations. This study attempted to identify biomarkers, pathogenesis, and therapeutic molecular targets for severe asthma in neutrophils using bioinformatics analysis.. Fifteen healthy controls and 3 patients with neutrophilic severe asthma were screened from the Gene Expression Omnibus (GEO) database. Based on the analysis of differentially expressed genes (DEGs), functional and pathway enrichment analyses, gene set enrichment analysis, protein-protein interaction network construction, and analysis were performed. Moreover, small-molecule drug candidates have also been identified.. Three hundred and three upregulated and 59 downregulated genes were identified. Gene ontology function enrichment analyses were primarily related to inflammatory response, immune response, leukocyte migration, neutrophil chemotaxis, mitogen-activated protein kinase cascade, Jun N-terminal kinase cascade, I-kappaB kinase/nuclear factor-κB, and MyD88-dependent toll-like receptor signaling pathway. Pathway enrichment analyses and gene set enrichment analysis were mainly involved in cytokine-cytokine receptor interaction, the TNF signaling pathway, leukocyte transendothelial migration, and the NOD-like receptor signaling pathway. Furthermore, 1 important module and 10 hub genes (CXCL8, TLR2, CXCL1, ICAM1, CXCR4, FPR2, SELL, PTEN, TREM1, and LEP) were identified in the protein-protein interaction network. Moreover, indoprofen, mimosine, STOCK1N-35874, trapidil, iloprost, aminoglutethimide, ajmaline, levobunolol, ethionamide, cefaclor, dimenhydrinate, and bethanechol are potential drugs for the treatment of neutrophil-predominant severe asthma.. This study identified potential biomarkers, pathogenesis, and therapeutic molecular targets for neutrophil-predominant severe asthma. Topics: Ajmaline; Aminoglutethimide; Asthma; Bethanechol; Biomarkers; Cefaclor; Computational Biology; Cytokines; Dimenhydrinate; Ethionamide; Gene Expression Profiling; Humans; Iloprost; Indoprofen; JNK Mitogen-Activated Protein Kinases; Levobunolol; Mimosine; Mitogen-Activated Protein Kinases; Myeloid Differentiation Factor 88; Neutrophils; NF-kappa B; NLR Proteins; Receptors, Cytokine; Toll-Like Receptor 2; Trapidil; Triggering Receptor Expressed on Myeloid Cells-1 | 2022 |
Prostaglandin I2 analogs suppress tumor necrosis factor α production and the maturation of human monocyte-derived dendritic cells.
Dendritic cells (DCs) are professional antigen-presenting cells and have critical roles in regulating immune responses. Prostaglandin I2 (PGI2) analogs are considered to be potential treatments for asthma. However, the effect of PGI2 analogs on human monocyte-derived DCs (MDDCs) is still not clearly understood.. Human MDDCs were pretreated with iloprost and treprostinil (2 PGI2 analogs) or forskolin (an adenyl cyclase activator) before lipopolysaccharide (LPS) stimulation. In some cases, I prostanoid (IP) receptor and E prostanoid receptor antagonists were added before the PGI2 analog treatment. tumor necrosis factor α (TNF-α) was measured by enzyme-linked immunosorbent assay. The expression of costimulatory molecules was assessed by flow cytometry. T-cell polarization function was investigated by measuring interferon γ, interleukin 13 (IL-13), and IL-17A production by T cells cocultured with iloprost-treated MDDCs.. Iloprost and treprostinil suppressed LPS-induced TNF-α expression in MDDCs. This effect could be reversed by an IP receptor antagonist, CAY10449, but not by E prostanoid receptor antagonists. Forskolin conferred a similar effect. Iloprost suppressed the LPS-induced expression of costimulatory molecules, including CD80, CD86, CD40, and HLA-DR. Iloprost-treated MDDCs increased IL-17A production by T cells.. Prostaglandin I2 analogs may exert anti-inflammatory effects by suppressing TNF-α expression via the IP receptor-cyclic adenosine monophosphate pathways and by inhibiting the expression of costimulatory molecules in human MDDCs. Topics: Asthma; Benzophenones; Cyclic AMP; Dendritic Cells; Epoprostenol; Humans; Iloprost; Imidazoles; Immune System; Leukocytes, Mononuclear; Lipopolysaccharides; Monocytes; Receptors, Prostaglandin E, EP1 Subtype; Tumor Necrosis Factor-alpha; Vasodilator Agents | 2011 |
Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function.
Inhalation of iloprost, a stable prostacyclin (PGI(2)) analog, is a well-accepted and safe treatment for pulmonary arterial hypertension. Although iloprost mainly acts as a vasodilator by binding to the I prostanoid (IP) receptor, recent evidence suggests that signaling via this receptor also has antiinflammatory effects through unclear mechanisms. Here we show in a murine model of asthma that iloprost inhalation suppressed the cardinal features of asthma when given during the priming or challenge phase. As a mechanism of action, iloprost interfered with the function of lung myeloid DCs, critical antigen-presenting cells of the airways. Iloprost treatment inhibited the maturation and migration of lung DCs to the mediastinal LNs, thereby abolishing the induction of an allergen-specific Th2 response in these nodes. The effect of iloprost was DC autonomous, as iloprost-treated DCs no longer induced Th2 differentiation from naive T cells or boosted effector cytokine production in primed Th2 cells. These data should pave the way for a clinical effectiveness study using inhaled iloprost for the treatment of asthma. Topics: Administration, Inhalation; Animals; Anti-Asthmatic Agents; Asthma; Cell Differentiation; Dendritic Cells; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Iloprost; Lung; Mice; Mice, Inbred BALB C; Mice, Transgenic; Ovalbumin; Th2 Cells | 2007 |